131 related articles for article (PubMed ID: 27236770)
1. Are the Formulas Used to Estimate Renal Function Adequate for Patients Treated With Cisplatin-Based Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Carcinoma?
Niwa N; Kikuchi E; Masashi M; Tanaka N; Nishiyama T; Miyajima A; Saito S; Oya M
Clin Genitourin Cancer; 2016 Oct; 14(5):e501-e507. PubMed ID: 27236770
[TBL] [Abstract][Full Text] [Related]
2. Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma.
Hashimoto T; Ohno Y; Nakashima J; Gondo T; Nakagami Y; Namiki K; Horiguchi Y; Yoshioka K; Ohori M; Tachibana M
Jpn J Clin Oncol; 2015 Nov; 45(11):1064-8. PubMed ID: 26355160
[TBL] [Abstract][Full Text] [Related]
3. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.
Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G
BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050
[TBL] [Abstract][Full Text] [Related]
4. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
Yafi FA; Tanguay S; Rendon R; Jacobsen N; Fairey A; Izawa J; Kapoor A; Black P; Lacombe L; Chin J; So A; Lattouf JB; Bell D; Fradet Y; Saad F; Matsumoto E; Drachenberg D; Cagiannos I; Kassouf W
Urol Oncol; 2014 Jan; 32(1):31.e17-24. PubMed ID: 23428535
[TBL] [Abstract][Full Text] [Related]
6. [Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma].
Li X; Sheng XN; Chi ZH; Cui CL; Si L; Mao LL; Tang BX; Lian B; Wang X; Yan XQ; Li SM; Bai X; Zhou L; Kong Y; Dai J; Guo J
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2574-2578. PubMed ID: 30220142
[No Abstract] [Full Text] [Related]
7. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
[TBL] [Abstract][Full Text] [Related]
8. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy.
Raman JD; Lin YK; Kaag M; Atkinson T; Crispen P; Wille M; Smith N; Hockenberry M; Guzzo T; Peyronnet B; Bensalah K; Simhan J; Kutikov A; Cha E; Herman M; Scherr D; Shariat SF; Boorjian SA
Urol Oncol; 2014 Jan; 32(1):47.e9-14. PubMed ID: 24140248
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy of Postoperative Adjuvant Chemotherapy for Patients with pT3N0M0 Upper Tract Urothelial Carcinoma.
Huang YC; Chen MF; Shi CS; Shindel AW; Huang CE; Pang ST; Chuang CK; Chen CS; Chang YH; Lin WY; Ho DR; Chin CC; Kuo YH; Wu CF
J Urol; 2015 Aug; 194(2):323-9. PubMed ID: 25796114
[TBL] [Abstract][Full Text] [Related]
10. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX
Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma].
Tsujimura A; Takayama H; Tsukikawa M; Imazu T; Sugao H; Takaha M
Hinyokika Kiyo; 1995 Mar; 41(3):183-9. PubMed ID: 7741070
[TBL] [Abstract][Full Text] [Related]
12. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.
Fujita K; Inamoto T; Yamamoto Y; Tanigawa G; Nakayama M; Mori N; Tsujihata M; Azuma H; Nonomura N; Uemura M
Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093
[TBL] [Abstract][Full Text] [Related]
13. Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without Type 2 diabetes: the eGFR Study.
Maple-Brown LJ; Ekinci EI; Hughes JT; Chatfield M; Lawton PD; Jones GR; Ellis AG; Sinha A; Cass A; Hoy WE; O'Dea K; Jerums G; MacIsaac RJ;
Diabet Med; 2014 Jul; 31(7):829-38. PubMed ID: 24598003
[TBL] [Abstract][Full Text] [Related]
14. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy.
Shao IH; Lin YH; Hou CP; Juang HH; Chen CL; Chang PL; Tsui KH
Drug Des Devel Ther; 2014; 8():1985-90. PubMed ID: 25364228
[TBL] [Abstract][Full Text] [Related]
15. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
[TBL] [Abstract][Full Text] [Related]
16. Predictive ability of renal cortex enhancement in dynamic computed tomography for residual renal function after nephroureterectomy: Comparison with
Waseda Y; Saito K; Ishikawa Y; Kawano K; Yokoyama M; Ishioka J; Matsuoka Y; Morimoto S; Kihara K; Fujii Y
Int J Urol; 2019 Feb; 26(2):266-272. PubMed ID: 30368933
[TBL] [Abstract][Full Text] [Related]
17. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.
Kaag MG; O'Malley RL; O'Malley P; Godoy G; Chen M; Smaldone MC; Hrebinko RL; Raman JD; Bochner B; Dalbagni G; Stifelman MD; Taneja SS; Huang WC
Eur Urol; 2010 Oct; 58(4):581-7. PubMed ID: 20619530
[TBL] [Abstract][Full Text] [Related]
18. New classification of hydronephrosis on 18F-FDG-PET/CT predicts post-operative renal function and muscle-invasive disease in patients with upper urinary tract urothelial carcinoma.
Asai S; Fukumoto T; Watanabe R; Koyama K; Sawada Y; Noda T; Miura N; Yanagihara Y; Miyauchi Y; Miyagawa M; Kikugawa T; Saika T
Jpn J Clin Oncol; 2018 Nov; 48(11):1022-1027. PubMed ID: 30252103
[TBL] [Abstract][Full Text] [Related]
19. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
[TBL] [Abstract][Full Text] [Related]
20. A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study.
Inoue T; Miyazaki J; Ichioka D; Narita S; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Matsui Y; Fujie K; Habuchi T; Nishiyama H
BMC Cancer; 2018 Mar; 18(1):290. PubMed ID: 29540229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
